Best Life Sciences Companies in Philadelphia, United States
The 207 best Life Sciences companies in Philadelphia, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Century Therapeutics.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Philadelphia
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Century Therapeutics Developer of therapeutics for the treatment of autoimmune diseases and cancer 72Funding top 17%Growth top 30%Fin. health top 34%Market top 40% All 8 signals ▾Fundingtop 17% Growthtop 30% Fin. healthtop 34% Markettop 40% Moattop 42% Techbottom 45% Globalbottom 39% Newsbottom 23% Funding: Raised $410M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) Growth: Revenue +1557% YoY · 1 acquisition/expansion move in 24 mo rank vs industry peers · Fliar Intelligence Index 72/100 | $410M | 5 mo ago | 94 94 → 118 (+26%) · sector median -1% | 2018 | — | — | 1 award |
| 2 | Tmunity Therapeutics Leveraging the immunological potential of T cells to treat a wide range of diseases | $231M | 79 mo ago | 43 | 2015 | — | — | — |
| 3 | Passage Bio Developer of gene therapies for CNS rare diseases | $226M | 57 mo ago | 58 58 → 43 (-26%) · sector median -1% | 2017 | Stephen Squinto Co-Founder | — | — |
| 4 | Iroko European real estate investment expert, offering accessible and responsible savings solutions | $215M | 118 mo ago | 4 | 2007 | — | — | 1 partnership |
| 5 | Aro Biotherapeutics Developer of tissue-targeted genetic medicines for rare diseases | $177M | 30 mo ago | 47 | 2018 | Susan Dillon President & CEO | 91 patents Targeted siRNA delivery via FN3 domains binding CD71 for enzyme replacement therapy | — |
| 6 | Imvax Personalized immunotherapies targeting solid tumors, stimulating innate and adaptive immunity | $175M | 16 mo ago | 50 | 2015 | David Andrews Co-Founder & Chief Medical Officer | 21 patents Patents concentrated in health & consumer products | — |
| 7 | Prelude Therapeutics Developer of chromatin function targeting drugs for the treatment of cancer and rare diseases | $145M | 69 mo ago | 128 128 → 106 (-17%) · sector median -1% | 2016 | Kris Vaddi Founder & CEO | 311 patents Small‑molecule inhibitors of kinases and epigenetic enzymes for oncology therapeutics. | — |
| 8 | Carisma Therapeutics Developer of chimeric antigen receptor macrophages for the treatment of cancer | $142M | 44 mo ago | 34 | 2016 | Michael Klichinsky Co-Founder and Chief Scientific Officer | — | — |
| 9 | Context Therapeutics Developing T cell engaging bispecific antibody therapies for solid tumors | $131M | 25 mo ago | 7 | 2015 | — | — | 2 job openings |
| 10 | Interius Biotherapeutics Developer of gene therapies for treating multiple diseases | $129M | 24 mo ago | 25 25 → 19 (-24%) · sector median -1% | 2020 | — | 101 patents Engineered immune cell therapies and targeted gene delivery using mutant CSF1R and hepatocyte vectors | — |
| 11 | Trevena Developer of GPCR ligand technology based therapeutics for cardiovascular diseases and pain | $119M | 29 mo ago | 35 | 2007 | — | 233 patents Patents concentrated in chemistry & materials | — |
| 12 | iECURE Online genetic engineering tool for drug development | $115M | 42 mo ago | 7 | 2020 | Joseph Truitt CEO | — | 1 internship |
| 13 | MOBILion Systems Manufacturer of mass spectroscopy instruments for clinical solutions | $114M | 59 mo ago | 2 | 2015 | — | — | — |
| 14 | Braeburn Developing long acting formulation for opioid addiction | $110M | 101 mo ago | 48 | 2012 | — | 3 patents Vehicle temperature control systems for passenger and commercial vehicles. | — |
| 15 | Medical Guardian Provider of medical alert system for older adults | $105M | 65 mo ago | 178 178 → 380 (+113%) · sector median -1% | 2005 | Geoff Gross Founder & CEO | — | 1 job opening |
| 16 | Adaptimmune Developer of novel cancer immunotherapies to treat cancer and infectious disease | $104M | 140 mo ago | 449 | 2008 | Adrian Rawcliffe CEO | 2 patents Engineered T‑cell receptor therapies for targeted cancer immunotherapy | — |
| 17 | Amicus Therapeutics Developer of therapies for rare and orphan diseases | $91M | 32 mo ago | 517 517 → 593 (+15%) · sector median -1% | 2002 | Bradley Campbell President and Chief Executive Officer | 1,815 patents Recombinant lysosomal enzymes and chaperone therapies for Pompe and Fabry diseases | — |
| 18 | Limelight Bio Provider of AAV-based gene therapies to treat inherited diseases | $89M | 78 mo ago | — | 2016 | Sam Hall CEO & Director | — | — |
| 19 | Vitara Biomedical Provider of technology for improving premature newborns health | $85M | 20 mo ago | 48 | 1999 | James Mcglone CEO | 32 patents Neonatal respiratory support devices and cannulation systems for oxygen delivery and monitoring | 1 award |
| 20 | Fore Developer of therapies for cancer treatment | $81M | 13 mo ago | 41 | 2011 | — | — | — |
| 21 | Exegenesis Bio Developer of cell and gene therapies to treat multiple diseases | $80M | 59 mo ago | 22 | 2019 | Lijun Wang Co-Founder & Chief Technology Officer | — | — |
| 22 | Proscia Provider of an AI and cloud-based digital pathology solution for cancer diagnosis | $79M | 15 mo ago | 85 85 → 132 (+55%) · sector median -1% | 2014 | Nathan Buchbinder Co-Founder & Chief Strategy Officer | 64 patents AI-driven image analysis and workflow automation for digital pathology diagnostics | — |
| 23 | Tarsa Therapeutics Developer of oral treatment for postmenopausal osteoporosis | $79M | 106 mo ago | 2 | 2009 | — | — | — |
| 24 | Excision Developer of CRISPR-based therapies to cure viral infectious diseases | $71M | 64 mo ago | 48 | 2015 | Daniel Dornbusch CEO | — | — |
| 25 | Avid Developer of molecular imaging agents for chronic disease diagnosis | $70M | 203 mo ago | 107 | 2004 | — | 248 patents Patents concentrated in computing, sensing & instrumentation | — |
| 26 | Immunome Developer of antibody-based therapeutics for treating cancer | $54M | 61 mo ago | 37 | 2008 | — | 89 patents Antibody‑drug conjugates and chiral benzodiazepinone compounds for cancer therapy | — |
| 27 | Latus Developer of gene therapy medicines for neurological diseases 35Funding top 26%Moat top 31%Talent bottom 49%Market bottom 40% All 5 signals ▾Fundingtop 26% Moattop 31% Talentbottom 49% Marketbottom 40% Globalbottom 36% Funding: Raised $54.0M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 35/100 | $54M | 1 mo ago | — | 2022 | P Ghoroghchian CEO | — | — |
| 28 | Innocoll qaw | $53M | 52 mo ago | 92 | 1985 | Anthony Zook CEO & President | 2 patents Localized drug delivery devices for peripheral nerve block and local anesthesia | — |
| 29 | Enterin Developer of pharmaceuticals that repair the gut-brain axis to treat patient suffering from neurodegenerative… | $52M | 30 mo ago | 21 | 2016 | Michael Zasloff Founder | 113 patents Aminosterol and squalamine-derived pharmaceutical compounds and formulations | — |
| 30 | Verismo Therapeutics Developer of CAR-T cell therapies for cancer 16Funding top 32%Moat top 39%Tech bottom 43%Global bottom 38% All 6 signals ▾Fundingtop 32% Moattop 39% Techbottom 43% Globalbottom 38% Marketbottom 25% Newsbottom 21% Funding: Raised $50.0M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 16/100 | $50M | 1 mo ago | 9 | 2020 | — | — | 1 job opening · 1 partnership · 1 award |
| 31 | Vivodyne Developer of AI-based platform for lab-grown human tissues | $40M | 16 mo ago | 16 | 2021 | Dan Huh Co-Founder | — | 1 launch |
| 32 | Peroxitech Developer of therapeutics to treat and prevent acute lung injury | $25M | 42 mo ago | — | 2017 | Aron Fisher Co-Founder | 3 patents Therapeutic compositions for managing septic shock in critical care | — |
| 33 | Linnaeus Therapeutics Biotech developing small molecule therapies for cancer, guided by clinical experience | $16M | 4 mo ago | 5 | 2018 | Christopher Natale Co-Founder | — | 2 awards |
| 34 | Avstera Developer of therapeutics for the treatment of cancer | $13M | 32 mo ago | 4 | 2021 | Ajay Raju Co-Founder | — | — |
| 35 | Avammune Therapeutics Developer of small-molecule innate immune modulators for cancer therapy | $12M | 13 mo ago | — | 2019 | Aditya Kulkarni Co-Founder & CSO | — | 1 job opening |
| 36 | Instadiagnostics Point-of-care diagnostics platform delivering rapid, comprehensive healthcare solutions | $11M | 12 mo ago | 5 | 2015 | Johann deSa Founder | — | — |
| 37 | Panorama Medicine Provider of drug discovery platform for detecting RNA defects | $6M | 33 mo ago | 5 | 2018 | — | — | — |
| 38 | Avisi Technologies Developer of nano-materials 21News top 34%Talent top 41%Funding top 42%Moat top 47% All 8 signals ▾Newstop 34% Talenttop 41% Fundingtop 42% Moattop 47% Patentsbottom 42% Globalbottom 39% Innovationbottom 35% Marketbottom 30% News: 4 BI events in 12 mo (of 8 tracked, 1 types) · Top themes: Funding Talent: Analyst team rating 4/5 · 1 named leader on record rank vs industry peers · Fliar Intelligence Index 21/100 | $5M | 3 mo ago | 15 | 2017 | Rui Jiang Co-Founder & CEO | 4 patents Ophthalmic therapeutic devices for delivering/tuning eye disease treatments | 1 award |
| 39 | BioPhy Provider of AI operating system that accelerates the identification and development of the most promising… | $4M | 15 mo ago | — | 2019 | Daniel Sciubba Co-Founder | — | — |
| 40 | ZSX Medical Medical device company reinventing surgical closure in women's health | $4M | 15 mo ago | 9 | 2009 | Eric Rugart Co-Founder | — | — |
| 41 | FloBio Point-of-care diagnostic platform | $4M | 16 mo ago | 6 | 2017 | Scott Diamond Founder | 6 patents Medical diagnostic platforms for coagulation, platelet function, and drug effect analysis | — |
| 42 | NephroDI Therapeutics Developer of therapeutics for concentration disorders of the kidney | $4M | 24 mo ago | 5 | 2017 | Ish Khanna Co-Founder | — | — |
| 43 | Waypoint Orthopedics Provider of decision support solutions for orthopedic surgery 10Talent top 38%Funding bottom 46%Global bottom 37%Market bottom 17% All 4 signals ▾Talenttop 38% Fundingbottom 46% Globalbottom 37% Marketbottom 17% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Funding: Raised $3.0M across 8 rounds · 8 rounds over 5 yrs (1.6/yr) rank vs industry peers · Fliar Intelligence Index 10/100 | $3M | 3 mo ago | 2 | 2020 | Stephen Banco Founder | — | — |
| 44 | Toetal Solutions Provider of the platform that offers solutions for foot and ankle deformities 14Moat top 45%Innovation top 49%Patents bottom 49%Talent bottom 49% All 7 signals ▾Moattop 45% Innovationtop 49% Patentsbottom 49% Talentbottom 49% Fundingbottom 45% Globalbottom 33% Marketbottom 17% Moat: Editorial + unicorn rating 4/10 · IP moat: 3 patents Innovation: 3 patents (top 91% of patent-holders) · 3 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 14/100 | $2M | 1 mo ago | 2 | 2021 | William Rhoda Co-Founder | 3 patents Interphalangeal joint prosthetic devices and implantation techniques | — |
| 45 | CellVax Therapeutics Developer of cell-based cancer immunotherapy | $2M | 21 mo ago | 8 | 2020 | Fernando Kreutz CEO | — | — |
| 46 | Aum Lifetech Developer of immunotherapies for a wide of diseases | $1M | 15 mo ago | 9 | 2013 | — | 36 patents Patents concentrated in chemistry & materials | — |
| 47 | EpiVario Developer of small molecules to treat psychiatric disorders | $860K | 20 mo ago | 3 | 2017 | Thomas Kim President and CEO | 6 patents Inhibitors of ACSS2 enzyme for metabolic disease and cancer therapy. | — |
| 48 | BioLattice Developer of solutions for tissue repair and restoration | $849K | 3 mo ago | — | 2017 | Amelia Zellander Co-Founder & CEO | — | 1 internship |
| 49 | Trevarx Biomedical Developer of radiopharmaceutical platforms for the treatment of cancer | $500K | 10 mo ago | 2 | 2016 | — | — | — |
Top 12 Life Sciences companies in Philadelphia
#1
Public · Philadelphia, Pennsylvania · founded 2018 · 94 employees$410Mraised▾
Developer of therapeutics for the treatment of autoimmune diseases and cancer. The company's iPSC-derived cell therapy platform that integrates cutting-edge gene editing, protein engineering, technical development and manufacturing capabilities to generate allogeneic, iPSC-derived therapies for autoimmune diseases and cancer.
- Jan 2026Post IPO$135M
- Apr 2024Post IPO$60M
- Mar 2021Series C$160M
- Jul 2019Series C$250M
#2
Series A · Philadelphia, Pennsylvania · founded 2022$54Mraised▾
Developer of gene therapy medicines for neurological diseases. The company leverages precision delivery through Adeno-Associated Virus to target specific cells and tissues, to improve the lives of patients suffering from various central nervous system disorders.
- May 2026Series A$97M
- May 2024Series A$54M
#3
Series A · Philadelphia, Pennsylvania · founded 2020 · 9 employees$50Mraised▾
Developer of CAR-T cell therapies for cancer. The KIR-CAR cell therapy provides stimulation to the cell that enhances the T-cell activation and elimination of antigen-negative tumor cells. It provides a product SynKIR-meso for pancreatic cancer, ovarian cancer, and mesothelioma.
- Apr 2026Series A$28M
- Jul 2023Seed$19.2M
- Feb 2023Seed$7M
- Apr 2021Seed$16M
#4
Series B · Philadelphia, Pennsylvania · founded 2018 · 5 employees$15.8Mraised▾
Biotech developing small molecule therapies for cancer, guided by clinical experience. The company identifies and develops innovative treatments for various cancers by listening to and learning from clinical experiences. This approach leads to the identification of new therapeutic targets. They focus on translating clinical insights into effective therapies, with a commitment to advancing drug candidates into human trials safely and quickly. Their team possesses diverse skills and expertise to drive the development of transformative cancer treatments. They are dedicated to improving patient outcomes through innovative science and a deep understanding of the clinical landscape. The company is focused on small molecule agents, clinical experience, therapeutic targets, and cancer treatment.
- Feb 2026Series B$5M
- Aug 2025Series B$1.3M
- Jan 2025Grant (prize money)$1000K
- Aug 2024Series B$5.8M
#5
Series C · Philadelphia, Pennsylvania · founded 2015 · 50 employees$174.8Mraised▾
Personalized immunotherapies targeting solid tumors, stimulating innate and adaptive immunity. This biopharmaceutical company is dedicated to turning the complexity of solid tumors against themselves through personalized, whole tumor-derived immunotherapies. Their unique platform captures a tumor’s full antigen signature and uses it to stimulate the patient’s innate and adaptive immunity against remaining tumor cells. They are developing a diverse pipeline of personalized treatments with promising clinical data in Glioblastoma and preclinical data in multiple other solid tumors. The company focuses on research & development strategy and activities, clinical development, and potential product development to deliver therapies targeting solid tumors. They are committed to innovation in the field of personalized immunotherapy.
- Jan 2025Series C$29M
- Sep 2023Series C$23M
- Jul 2020Series C$112.4M
- May 2019Series B$24.8M
#6
Series A · Philadelphia, Pennsylvania · founded 2017 · 15 employees$5Mraised▾
Developer of nano-materials. It provides users with a platform that develops an ultrathin nanoplate made of alumina, implant material is developed in collaboration with the University of Pennsylvania for treating mid to late-stage glaucoma.
- Feb 2026Series A$10.7M
- Jan 2023Series A$4M
- Jan 2021Seed$1M
- Sep 2020Grant (prize money)$1M
#7
Seed · Philadelphia, Pennsylvania · founded 2021 · 2 employees$2.5Mraised▾
Provider of the platform that offers solutions for foot and ankle deformities. It offers the ZipToe Hammertoe System which consists of a sterile packed procedure kit and implant to address ridged hammertoe deformity.
- Apr 2026Seed$100K
- Sep 2024Seed$100K
- Mar 2024Seed$430K
- Dec 2023Seed$150K
#8
Series D · Philadelphia, Pennsylvania · founded 2011 · 41 employees$81Mraised▾
Developer of therapies for cancer treatment. The company's lead candidate FORE8394 is a small-molecule, next-generation, orally available selective inhibitor of mutated BRA for the treatment of tumors.
- Apr 2025Series D$38M
- Aug 2023Series D$75M
- Apr 2018Series A$6M
#9
Seed · Philadelphia, Pennsylvania · founded 2020 · 2 employees$3Mraised▾
Provider of decision support solutions for orthopedic surgery. The company offers the product Waypoint GPS. The features allow doctors to see the color of the bone as they traverse through the pedicle in preparation for screw placement. They also provide a smart pedicle probe that utilizes proprietary color-sensing technology.
- Mar 2026Seed$300K
- Sep 2025Seed$50K
- Jun 2025Seed$30K
- Dec 2024Seed$35K
#10
Series C · Philadelphia, Pennsylvania · founded 2014 · 85 employees$79.2Mraised▾
Proscia’s is a cloud-based software platform that clinic management, analysis, access, and collaboration for slide images in digital pathology. The features of the Proscia platform that allow users to improve whole slide image workflows include secure storage, annotation, and collaboration on digital biopsies. The company has developed a digital pathology platform called Concentriq that uses AI technology for computational pathology applications. The company has developed a tool that assists helathacre providers to diagnose cancer cells using image analysis technology.
- Mar 2025Series C$50M
- Dec 2023Series C$9M
- Jun 2022Series C$37M
- Nov 2020Series B$23M
#11
Series A · Philadelphia, Pennsylvania · founded 2021 · 16 employees$40Mraised▾
Developer of AI-based platform for lab-grown human tissues. The company's platform culture human tissue models for drug discovery and utilizes single-cell 4D phenomics with an integrated confocal microscope. Also, has an automated robotic system that discovers drugs and cellular therapies.
- Feb 2025Series A$77.7M
- Nov 2023Seed$38M
- Mar 2021Seed$2M
#12
Series C · Philadelphia, Pennsylvania · founded 1999 · 48 employees$85Mraised▾
Provider of technology for improving premature newborns health. It offers EXTEND a fluid-filled supportive environment inspired by the natural conditions of the womb intended to allow fragile lungs and other organs to develop safely outside the mother before full breathing ability begins.
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
What Philadelphia researches in biotechnology
Children's Hospital of Philadelphia and peers lead Philadelphia's optimistic biotech research, predominantly advancing CAR-T cell therapy, RNA splicing, and hemoglobinopathy treatments with minimal concern.
- Children\'s Hospital of Philadelphia31
- Philadelphia University5
- Philadelphia College of Osteopathic Medicine2
- Einstein Medical Center Philadelphia1
- Philadelphia VA Medical Center1
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.